Understanding Spasmomen (Diazepam/Otilonium Bromide)

Spasmomen is a combination medication that integrates two different active components: Otilonium bromide and Diazepam. This combination is primarily used to address functional gastrointestinal disorders where physical discomfort is accompanied by emotional or psychosomatic factors.

By combining an antispasmodic agent with a mild anxiolytic, the medication aims to manage both the physical contractions of the digestive tract and the underlying tension that often exacerbates these symptoms.

Main Uses

The primary application of this medication is in the management of conditions affecting the lower gastrointestinal tract. Its use is generally indicated for:

• Irritable Bowel Syndrome (IBS): Managing the symptoms associated with IBS, particularly when environmental or emotional stress triggers physical discomfort.
• Gastrointestinal Spasms: Relieving painful contractions of the smooth muscles in the gut.
• Psychosomatic Digestive Disturbance: Addressing digestive issues where anxiety or nervous tension plays a significant role in the frequency and intensity of the symptoms.
• Functional Colopathy: Treating chronic conditions of the colon that involve altered motility and discomfort without an identifiable structural cause.

Benefits and Mechanism of Action

The combination of Otilonium bromide and Diazepam provides a dual approach to gastrointestinal care:

Targeted Spasm Relief

Otilonium bromide acts locally on the smooth muscles of the digestive tract. It works as an antispasmodic by blocking calcium channels and interfering with the triggers that cause muscle fibers to contract excessively. This helps to normalize gut motility and reduce the pain associated with cramping.

Reduction of Somatic Tension

Diazepam belongs to the benzodiazepine class and acts on the central nervous system. In this specific combination, it is included in a low dose to help reduce the anxiety and emotional stress that often manifest as physical symptoms in the gut. By lowering the "stress signal" sent to the digestive system, it helps stabilize the brain-gut axis.

Improvement of Quality of Life

By addressing both the physical spasm and the psychological tension, the medication helps to:

• Reduce the frequency of painful abdominal episodes.
• Lower the intensity of cramping and bloating.
• Stabilize bowel habits impacted by nervous stress.

Who Can and Cannot Use Spasmomen (Otilonium Bromide, Diazepam)?

This medicine is a prescription-only combination drug, and its use is strictly determined by official regulatory criteria. These rules define who is eligible to use the medicine and who is prohibited due to underlying health conditions or age.

---

Populations for Prohibited or Restricted Use

Classification	Population/Condition	Restriction Basis
Absolute Contraindication	Glaucoma (Acute Narrow-Angle), Severe Hepatic Insufficiency, Myasthenia Gravis, Pyloric Stenosis, or Hypersensitivity to ingredients.	Due to anticholinergic action or CNS effects.
Use Not Established	Children and Adolescents under 18 years.	Safety and efficacy data are lacking.
Conditional Use Only	Pregnancy and Lactation (Breastfeeding).	Use should be avoided unless absolutely necessary and closely supervised.
Caution Required	Prostatic Hypertrophy (enlargement) or Chronic Respiratory Insufficiency.	Requires medical caution to manage potential risks.

---

Approved Age Group

Spasmomen is officially intended for use only in adults (patients 18 years of age and older). Use in pediatric patients is not recommended by regulatory authorities.

The official interaction profile for this combination medication is defined by the systemic activity of the Diazepam component, as regulatory documents indicate Otilonium Bromide has negligible systemic absorption and interaction relevance.

Interaction Restrictions

The highest restriction involves Opioids, where co-administration is subject to an FDA Boxed Warning due to the risk of profound sedation, respiratory depression, and death. Alcohol and various classes of CNS depressants (including antipsychotics, hypnotics, and narcotic analgesics) are also restricted because they exhibit pharmacodynamic potentiation, increasing the severity of sedation and central depressant effects.

Clearance and Exposure

A major interaction domain involves pharmacokinetic clearance modification via the CYP3A4 and CYP2C19 enzymes. Agents such as Cimetidine, Omeprazole, and Fluoxetine inhibit these enzymes, officially resulting in decreased elimination, which increases drug exposure and leads to prolonged sedation. Valproate is reported to increase the free fraction of the active component by displacing it from plasma binding sites.

Food and Population Notes

Antacids and consumption of a moderate fat meal delay and decrease the overall rate of drug absorption. Population-specific considerations require caution when co-administering with CNS depressants in the elderly and in patients with compromised hepatic or kidney function due to the risk of metabolite accumulation. No mandatory timing separation rules are defined in the regulatory labels.

The mechanism involves the combined action of two distinct molecules. Diazepam, a benzodiazepine, acts as a positive allosteric modulator at the GABA A receptor complex in the central nervous system, particularly targeting regions like the limbic system and spinal cord. Its binding site is located between the alpha and gamma subunits, which allosterically enhances the affinity of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) for its binding site. This allosteric modulation increases the frequency of chloride channel opening, promoting the influx of chloride ions ( Cl^-) and leading to the hyperpolarization of the neuronal membrane. This increased hyperpolarization decreases the excitability of the neuron, resulting in reduced signal transmission within the central and spinal pathways responsible for motor control.

In parallel, Otilonium Bromide exerts a peripheral, local action primarily in the gastrointestinal tract. As a quaternary ammonium compound, it functions as an antispasmodic by acting as a calcium channel blocker and a muscarinic receptor antagonist. Otilonium Bromide primarily blocks the influx of calcium ions ( Ca^2+) through L-type voltage-gated calcium channels on the plasma membrane of smooth muscle cells. This action limits the intracellular Ca^2+ concentration, which is essential for the activation of the contractile machinery in smooth muscle. Simultaneously, it also exhibits competitive antagonism at peripheral muscarinic receptors. The resulting reduction in intracellular Ca^2+ and inhibited cholinergic signaling leads to the modulation of intestinal smooth muscle contractility.

Official Administration Guidelines

Spasmomen, a product containing Otilonium Bromide and Diazepam, follows the administration protocols established for the primary active component, Otilonium Bromide 40 mg. The medicine is intended for oral administration as a film-coated tablet and is approved only for the adult population (patients over 18 years of age); its use is not recommended for children or adolescents.

Standard Dosing and Timing

The standardized regimen defines the administration pattern. The typical single dose is one 40 mg tablet, with a total daily dosage ranging between 80 mg and 120 mg. This is generally administered 2 to 3 times daily. A specific instruction indicates that each dose be taken, preferably, 20 minutes before meals.

Administration Protocol

The film-coated tablet must be swallowed whole with a glass of water; it should not be broken, crushed, or chewed. If a dose is missed, it should be taken as soon as remembered, but the missed dose should be skipped if it is close to the time of the next scheduled dose, thereby preventing the intake of a double dose. The treatment course has no fixed limit but involves periodic medical re-assessment to determine the necessity of continued use, as the total duration depends on the specific condition.

Evidence for use in Irritable Bowel Syndrome (IBS)

The primary research for the antispasmodic component, Otilonium Bromide, involves large Randomized Controlled Trials (RCTs). These double-blind studies typically use a placebo and focus on Adults with Irritable Bowel Syndrome (IBS) over time-limited intervals (4 to 15 weeks). Researchers measure patient-reported outcomes related to physical discomfort, including abdominal pain, abdominal distension (bloating), and global symptom relief. Studies monitored how symptoms evolved across groups.

Limited studies have explored the specific Otilonium Bromide and Diazepam combination, evaluating outcomes related to physical discomfort alongside measures of associated systemic or functional imbalance, such as nervous tension. The overall body of research concentrates heavily on the antispasmodic component alone.

---

Comparing the Active Component to Placebo and Other Treatments

Research highlights changes measured when comparing the drug's primary component against a placebo. Beyond this, some studies were conducted as active-controlled trials, where the agent was evaluated against other commonly used antispasmodics. These findings describe group patterns related to observed response, but research does not determine whether an individual will respond similarly.

---

Long-term Follow-up and Durability of Effect

Most available research explores short-term changes during treatment periods up to 15 weeks. While studies monitored patients to assess the time to symptom relapse after the medication ceased, the follow-up durations were limited. Long-term effects are not fully established, and research is ongoing in this area.

---

Evidence in Specific Patient Groups

The majority of studies examined Adult populations who met standardized criteria for IBS. Subgroup findings are uncertain for many groups, and data for certain groups remain insufficient, such as pediatric patients. The results apply only to the populations studied in the RCTs.

---

What is Still Uncertain About the Combination

Evidence is limited regarding the optimal duration of treatment. Comparative evidence is lacking for large-scale trials evaluating the specific Otilonium Bromide and Diazepam combination against the single agent alone. Evidence quality varies, and some trials were noted to have modest sample sizes. Certainty remains low regarding the pattern of response and long-term consequences of the combination in all potential patient subgroups.

Key Studies & References

1. [Otilonium bromide-diazepam in the treatment of the irritable colon. A controlled study versus otilonium bromide]
2. Minutes of the 53rd meeting of the Medicines Classification Committee - 5 May 2015 (Otilonium bromide classification)

Common questions about Spasmomen (Diazepam,Otilonium Bromide) (FAQ)

Q: How long will I have to take Spasmomen for?

Official prescribing information indicates there is no fixed time limit for taking this medicine. The total duration of use depends on the course of your condition. Periodic medical re-assessment is required to determine the necessity of continued use.

---

Q: Is there a risk of becoming addicted to Spasmomen?

Since Spasmomen contains Diazepam, a benzodiazepine, official safety information indicates a risk. Prolonged use of the medicine is associated with the development of physical and psychological dependence, as well as withdrawal syndrome.

---

Q: Can I take Spasmomen if I have glaucoma?

Official regulatory documents indicate that Spasmomen is absolutely contraindicated for use in people with Acute Narrow-Angle Glaucoma. The product label notes that caution may be needed for patients with other forms of increased eye pressure (glaucoma).

---

Q: Can I drink alcohol while taking this medicine?

Regulatory warnings state that using alcohol with this medicine may intensify the risk of central depressant effects, such as sedation. This happens because alcohol increases the severity of the central depressant effects of the Diazepam component.

---

Q: Are there any dietary restrictions I need to follow while on Spasmomen?

Official interaction information notes that consuming a moderate fat meal can affect how the drug works. It is reported to delay and decrease the overall rate at which the medication is absorbed by your body.

---

Q: Can I stop taking Spasmomen immediately if I feel better?

The official safety profile states that after prolonged use, there is a risk of developing a withdrawal syndrome when the medicine is stopped. Because of this risk, any changes to the treatment plan, including stopping the medicine, should be reviewed by a healthcare professional.

The official regulatory requirements for storing and disposing of Spasmomen tablets are designed to maintain product integrity and ensure public safety.

Storage Requirements

Condition	Requirement
Temperature	Store at or below 30 C (thirty degrees Celsius).
Packaging	Keep the medicine in the original outer carton and blister strips.
Safety Rule	Keep this medicine out of the sight and reach of children.

Disposal Instructions

• Do not use the tablets after the expiry date stated on the packaging.
• Do not throw away any medicines via wastewater or household waste.
• You must ask your pharmacist how to throw away medicines you no longer use. These measures are required to help protect the environment.